Prevention of type 2 diabetes in HIV: a pilot study of effectiveness and acceptability

Submission date	Recruitment status No longer recruiting	Prospectively registered		
30/01/2014		Protocol		
Registration date 30/01/2014	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 15/10/2020	Condition category Infections and Infestations	[] Individual participant data		

Plain English summary of protocol

Background and study aims

The risk of HIV patients developing diabetes has been reported to be up to four times higher compared to those without HIV. Lifestyle modifications can prevent type 2 diabetes in the general population; given the differences in the cause of diabetes in HIV, and potential HIV-specific barriers to lifestyle change, it is important to develop effective methods in this population. Therefore, this study aims to find out an effective lifestyle intervention for treating diabetes in HIV.

Who can participate?

The study is open to people living with HIV registered as patients at Guy's and St Thomas' Hospital in London, UK

What does the study involve?

Part 1: In this comparison study, 162 participants grouped according to blood glucose levels have factors associated with type 2 diabetes studied.

Part 2: In this initial study up to 46 patients with insulin resistance receive 6 months of advice to change diet and physical activity. Change in insulin resistance is measured.

Part 3: Participants are interviewed to assess the acceptability of the intervention, and describe what helps and what hinders lifestyle change.

Part 4: Two focus groups of 6-10 participants discuss findings to aid the design of a future large-scale study.

What are the possible benefits and risks of participating?

Participants with pre-diabetes are eligible to take part in a 6-month intervention aiming to reduce their risk of developing diabetes; however, this is an initial study and the degree of potential success is not yet known. Participants in the study will help define risk factors for developing type 2 diabetes.

Where is the study run from?
Guy's and St Thomas' Hospital (UK)

When is the study starting and how long is it expected to run for? December 2013 to August 2015

Who is funding the study? National Institute for Health Research (NIHR) (UK)

Who is the main contact? Mr Alastair Duncan alastair.duncan@gstt.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Mr Alastair Duncan

Contact details

St Thomas's Hospital 249 Westminster Bridge Road London United Kingdom SE1 7EH

-

alastair.duncan@gstt.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

 ${\bf Clinical Trials. gov\ number}$

Secondary identifying numbers 15786

Study information

Scientific Title

Prevention of type 2 diabetes in HIV: a pilot study of effectiveness and acceptability: a non-randomised controlled trial

Acronym

STOP Diabetes

Study objectives

- 1. Can individualised lifestyle advice reduce insulin resistance in HIV patients with pre-diabetes?
- 2. Is this advice acceptable to participants?
- 3. Are barriers to lifestyle change HIV-specific?

Ethics approval required

Old ethics approval format

Ethics approval(s)

13/LO/1543; First MREC approval date 11/11/2013

Study design

Non-randomised; Interventional; Design type: Prevention, Treatment

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Diabetes Research Network, Infection; Subtopic: Type 2, Infection (all Subtopics); Disease: Diabetic Control, Infectious diseases and microbiology, Education

Interventions

Lifestyle advice, 6 months of individualised diet and physical activity advice; Follow Up Length: 6 month(s); Study Entry: Registration only

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Change in insulin resistance; Timepoint(s): Measured by frequently sampled liquid meal tolerance test at Day 1 and Day 180

Secondary outcome measures

- 1. Blood pressure; Timepoint(s): day 1 and day 180
- 2. Change in anthropometry; Timepoint(s): day 1 and day 180
- 3. Change in dietary intake; Timepoint(s): day 1 and day 180
- 4. Change in lipids; Timepoint(s): day 1 and day 180
- 5. Change in physical activity; Timepoint(s): day 1 and day 180
- 6. Quality of life; Timepoint(s): day 1 and day 180

Overall study start date

23/12/2013

Completion date

27/08/2015

Eligibility

Key inclusion criteria

Part 1:

- 1. HIV positive adults aged 18 years
- 2. Are competent in English language

Part 2:

- 1. HIV positive adults aged 18 years old
- 2. Stable on current antiretrovirals for last 6 months
- 3. Unlikely to need to change their antiretrovirals within the next 6 months
- 4. Have insulin resistance (fasting glucose 5.6 6.9 mmol/l)
- 5. Able to give informed consent
- 6. Willing and able to participate in an exercise programme
- 7. Able to attend monthly appointments for 6 months
- 8. In the opinion of the investigator will be unlikely to have any planned events within the next 6 months that would prevent adherence to a lifestyle change programme
- 9. Competent in English language

Part 3:

- 1. Those exiting Part 2 after completing the 6 month intervention
- 2. Those who withdraw from Part 2 after the initial visit and before completing the 6 month intervention
- 3. Those who were eligible for Part 2, declined the intervention, but consented to interview

Part 4:

- 1. HIV positive expert patient or patient representative, or an HIV advocate
- 2. Health professional working in HIV care

Participant type(s)

Patient

Age group

Adult

Lower age limit

Sex

Both

Target number of participants

Planned Sample Size: 162; UK Sample Size: 162

Total final enrolment

28

Key exclusion criteria

Part 1:

- 1. Unable to attend for a single visit
- 2. Type 1 diabetes

Part 2:

- 1. Have a clinical diagnosis of type 1 or type 2 diabetes
- 2. Have a fasting glucose indicative of diabetes (=7.0 mmol /l)
- 3. Have a random glucose indicative of diabetes (=11.1 mmol/l)
- 4. Are pregnant, planning for a pregnancy, or lactating
- 5. Are naive to antiretroviral therapy
- 6. Have medical problems that may interfere with patient safety
- 7. Have a current medical condition that makes exercise inadvisable
- 8. Are fitted with an artificial cardiac pacemaker device
- 9. Have liver impairment suggested by liver function tests (ALT) within the last year elevated =2.
- 5 times above the upper level of the laboratory reference range
- 10. Have hepatitis B and/or C coinfection
- 11. Use medicines that might interfere with glucose homeostasis measures, e.g. corticosteroids, anabolic steroids, testosterone or diabetes medications

Part 3:

1. Are unable to undertake the interview within two weeks of withdrawing/completing, as beyond this time the participants history may change as elements are forgotten.

Part 4:

1. Are unable to attend a single focus group

Date of first enrolment

23/12/2013

Date of final enrolment

01/07/2015

Locations

Countries of recruitment

England

United Kingdom

Study participating centre St Thomas's Hospital London United Kingdom SE1 7EH

Sponsor information

Organisation

Guy's and St Thomas' NHS Foundation trust (UK)

Sponsor details

Asthma Allery & Respiratory science London England United Kingdom SE1 7EH

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/00j161312

Funder(s)

Funder type

Government

Funder Name

NIHR Doctoral Research Fellowship; Grant Codes: CDRF-2012-03-021

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration

Study outputs

Output type	Details results	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/10/2020	15/10/2020	Yes	No
HRA research summary			28/06/2023	No	No